Back to today’s briefing

Story perspectives

Revolution Medicines' Drug Doubles Survival in Pancreatic Cancer Trial

4/13/2026

42 4 Full Breakdown

Summary

Story summary

Revolution Medicines Inc. announced Phase 3 results for the oral drug daraxonrasib in metastatic pancreatic cancer, showing median overall survival of 13.2 months versus 6.7 months with chemotherapy.
The trial met all primary and secondary endpoints.
The announcement triggered a 40% surge in Revolution Medicines Inc.'s stock.
Revolution plans to submit the findings to the U.S. FDA using a priority voucher to expedite approval.

1 of 1

Story summary

Revolution Medicines Inc. announced Phase 3 results for the oral drug daraxonrasib in metastatic pancreatic cancer, showing median overall survival of 13.2 months versus 6.7 months with chemotherapy.
The trial met all primary and secondary endpoints.
The announcement triggered a 40% surge in Revolution Medicines Inc.'s stock.
Revolution plans to submit the findings to the U.S. FDA using a priority voucher to expedite approval.